Sipavibart
Medication
From Wikipedia, the free encyclopedia
Sipavibart, sold under the brand name Kavigale, is a medication used for the prevention of COVID-19 in people who are immunocompromised.[3] Sipavibart is a recombinant human IgG1 monoclonal antibody that provides passive immunization against SARS-CoV-2 by binding its spike protein receptor binding domain.[3][5]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | SARS-CoV-2 |
| Clinical data | |
| Trade names | Kavigale |
| Other names | AZD-3152 |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Sipavibart was authorized for medical use in the European Union in January 2025.[3][4]
Medical uses
Society and culture
Legal status
In December 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Kavigale, intended for the prevention of COVID-19 in immunocompromised people aged twelve years of age and older.[3] Kavigale was reviewed under the EMA's accelerated assessment program.[3] The applicant for this medicinal product is AstraZeneca AB.[3] Sipavibart was authorized for medical use in the European Union in January 2025.[3][4]
Names
Sipavibart is the international nonproprietary name.[6]
.svg){kind=small}
